+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Prostate Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Prostate Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896567
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Cancer Therapeutics Market is projected to reach USD 11.84 Billion in 2026. It is expected to continue growing at a CAGR of 6.64%, reaching USD 17.59 Billion by 2032.

Prostate cancer therapeutics are moving from a historically hormone-centered category toward a precision oncology model that combines androgen deprivation therapy, androgen receptor pathway inhibitors, taxanes, PARP inhibitors, PSMA-targeted radiopharmaceuticals, immunotherapy for selected biomarker-defined patients, and supportive bone-targeted care. The clinical need remains substantial: GLOBOCAN 2022 estimated more than 1.46 million new prostate cancer cases and approximately 397,000 deaths worldwide, making prostate cancer one of the most frequently diagnosed cancers in men.

Market momentum is being shaped by earlier treatment intensification, improved genomic testing, expanded PSMA PET imaging, and broader use of therapies across metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer. For industry stakeholders, the competitive frontier is increasingly defined by survival benefit, tolerability, sequencing evidence, real-world outcomes, diagnostic infrastructure, and payer confidence in high-value innovation.

Transformative Shifts in the Prostate Cancer Treatment Landscape

The prostate cancer treatment landscape is being reshaped by the migration of advanced therapies into earlier lines of care. Treatment intensification with androgen receptor pathway inhibitors in metastatic hormone-sensitive disease has changed standard practice, while non-metastatic castration-resistant prostate cancer has become a key setting for delaying metastasis and extending survival.

Precision medicine is another defining shift. Regulatory approvals for PARP inhibitors in selected patients with homologous recombination repair alterations and PSMA-targeted radioligand therapy for eligible metastatic castration-resistant disease have established biomarker-enabled treatment as a major clinical and commercial driver. At the same time, demand for PSMA PET imaging, next-generation sequencing, liquid biopsy, and multidisciplinary treatment pathways is increasing the strategic value of diagnostics partnerships and integrated care models.

Cumulative Impact of Artificial Intelligence in Prostate Cancer Therapeutics

Artificial intelligence is becoming a cumulative enabler across prostate cancer therapeutics, not a single-point disruption. In discovery and translational research, AI supports target prioritization, molecular pattern recognition, and trial enrichment by analyzing genomic, imaging, pathology, and clinical datasets. These capabilities can help developers identify responsive subpopulations and reduce the risk of underpowered or poorly selected trials.

In clinical practice, AI-assisted pathology and radiology may improve risk stratification, lesion detection, and treatment planning when validated against rigorous clinical standards. In commercialization, AI-driven real-world evidence analytics can help manufacturers understand treatment sequencing, adherence, toxicity patterns, and health equity gaps. The strongest opportunity lies in responsibly governed AI systems that improve decision support while protecting patient privacy, reducing bias, and aligning with regulatory expectations.

Key Regional Insights: Global Adoption Patterns

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia strengthen oncology infrastructure, broaden access to advanced imaging, and increase adoption of novel hormonal agents. Japan, South Korea, and Australia benefit from mature reimbursement and specialist networks, while China is scaling cancer care capacity and India is improving access through large tertiary oncology centers despite affordability constraints. North America remains a leading innovation and reimbursement region, supported by high disease awareness, advanced diagnostics, academic trial networks, and regulatory approvals for radioligand and biomarker-directed therapies.

Latin America shows growing demand but uneven access, with Brazil and Mexico acting as important treatment hubs while reimbursement constraints and fragmented health coverage influence uptake of premium therapies. Europe benefits from strong guideline adoption, cancer registries, multidisciplinary urology-oncology care, and expanding PSMA PET and genomic testing capabilities, although pricing, procurement, and health technology assessment requirements vary by country.

The Middle East, led by Gulf health system investment, is increasing access to oncology centers, nuclear medicine capacity, and specialty care for advanced prostate cancer. Africa continues to face underdiagnosis, late presentation, and limited access to advanced therapeutics in many markets, making diagnostic capacity, workforce training, pathology services, radiotherapy availability, and affordable treatment pathways essential to long-term development.

Key Group Insights: Strategic Market Clusters

ASEAN markets are gaining relevance as urban oncology centers expand access to hormonal therapies, imaging, and specialist care, though reimbursement variation remains a barrier to consistent adoption of advanced prostate cancer therapeutics. The GCC is positioned for faster uptake due to investment in specialty hospitals, nuclear medicine infrastructure, digital health programs, and national cancer strategies that support earlier diagnosis and centralized cancer care.

The European Union remains central to evidence-based adoption because centralized regulatory review is followed by country-level health technology assessment, reimbursement decisions, and pricing negotiations. BRICS countries represent a significant treatment-access opportunity, combining large patient populations with policy efforts to localize manufacturing, expand cancer services, strengthen screening awareness, and improve availability of innovative oncology medicines.

G7 countries continue to influence clinical guidelines, pricing benchmarks, regulatory standards, real-world evidence expectations, and adoption of precision oncology tools such as genomic testing and PSMA PET imaging. NATO members overlap substantially with North American and European high-income markets, where supply chain resilience, radiopharmaceutical logistics, isotope access, cybersecurity, and secure health data infrastructure are becoming increasingly relevant to oncology care continuity.

Key Country Insights: Priority Prostate Cancer Markets

The United States anchors global prostate cancer therapeutics innovation, with the American Cancer Society estimating about 299,010 new prostate cancer cases and 35,250 deaths in 2024, supported by broad access to clinical trials, advanced imaging, genomic testing, and specialty oncology care. Canada benefits from organized cancer systems and growing precision oncology adoption, while Mexico and Brazil show rising demand amid unequal access across public and private health systems and increasing reliance on major urban oncology centers.

The United Kingdom, Germany, France, Italy, and Spain are influential European markets shaped by guideline-driven care, national reimbursement decisions, multidisciplinary cancer networks, and expanding use of advanced diagnostics. Germany and France maintain strong oncology infrastructure, the United Kingdom emphasizes evidence-based access through national assessment pathways, and Italy and Spain continue to advance specialist care delivery across regional health systems. Russia remains a sizable market by population but faces access, reimbursement, and supply considerations that influence adoption of newer prostate cancer agents.

China is scaling oncology access, genomic medicine, nuclear medicine capacity, and domestic innovation, while India has high long-term treatment need but significant affordability and access constraints outside leading metropolitan cancer centers. Japan maintains strong adoption of advanced therapies under a structured reimbursement system, Australia offers mature cancer care and active clinical trial participation, and South Korea combines advanced diagnostics, digital health capability, and a competitive biopharmaceutical ecosystem to support precision prostate cancer treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates overall survival, radiographic progression-free survival, quality of life, safety, and real-world value across clearly defined prostate cancer patient segments. Organizations that integrate companion diagnostics, PSMA imaging pathways, and genomic testing support into commercialization plans will be better positioned to capture biomarker-driven demand.

Strategic focus should also include treatment sequencing research, radiopharmaceutical supply chain resilience, isotope availability planning, referral pathway optimization, and differentiated patient support programs. In cost-sensitive markets, tiered access models, local partnerships, physician education, and health economic evidence will be critical for sustainable growth in prostate cancer therapeutics.

Research Methodology

This executive summary is developed through triangulation of publicly available epidemiology, regulatory, clinical, and market-access sources. Core references include global cancer burden estimates, national cancer statistics, regulatory approvals, clinical guideline trends, peer-reviewed trial evidence, oncology infrastructure indicators, and publicly available health system information.

The analysis emphasizes verified disease burden, approved therapeutic classes, observable adoption drivers, documented infrastructure trends, and evidence-based access considerations. Insights are synthesized to support strategic decision-making across pharmaceutical development, diagnostics integration, regional access planning, and competitive positioning in prostate cancer therapeutics, while avoiding market sizing, market share estimation, and forecasting.

Conclusion

The prostate cancer therapeutics category is entering a new era defined by precision treatment, earlier intensification, PSMA-targeted radioligand innovation, and data-enabled care delivery. While high-income markets lead adoption of advanced agents, the largest long-term opportunities will come from improving diagnosis, genomic testing, imaging access, affordability, and treatment continuity across emerging regions.

Organizations that combine differentiated clinical evidence with diagnostic integration, AI-enabled real-world insights, radiopharmaceutical readiness, and regionally tailored access strategies will be best positioned to compete in this evolving oncology category.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism
7.1. Introduction
7.2. Chemotherapy
7.2.1. Platinum Compounds
7.2.2. Taxanes
7.3. Hormone Therapy
7.3.1. Antiandrogens
7.3.2. CYP17 Inhibitors
7.3.3. GnRH Agonists
7.3.4. GnRH Antagonists
7.4. Immunotherapy
7.4.1. Cancer Vaccines
7.4.2. Cell Therapy
7.4.3. Checkpoint Inhibitors
7.5. Radiopharmaceuticals
7.5.1. Alpha Emitters
7.5.2. Beta Emitters
7.6. Targeted Therapy
7.6.1. Monoclonal Antibodies
7.6.2. Parp Inhibitors
7.6.3. Tyrosine Kinase Inhibitors
8. Prostate Cancer Therapeutics Market, by Therapy Line
8.1. Introduction
8.2. First Line
8.3. Second Line
8.4. Third Line & Beyond
9. Prostate Cancer Therapeutics Market, by Formulation
9.1. Introduction
9.2. Injectable
9.3. Oral
10. Prostate Cancer Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Prostate Cancer Therapeutics Market, by End User
11.1. Introduction
11.2. Cancer Centers
11.3. Homecare Providers
11.4. Hospitals
11.5. Specialty Clinics
12. Prostate Cancer Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Prostate Cancer Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Prostate Cancer Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Astellas Pharma Inc.
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. Bristol-Myers Squibb Company
16.7. Eisai Inc.
16.8. Eli Lilly and Company
16.9. F. Hoffmann-La Roche AG
16.10. Genentech, Inc.
16.11. GlaxoSmithKline plc
16.12. Ipsen S.A.
16.13. Johnson & Johnson Services Inc.
16.14. Merck & Co., Inc.
16.15. Novartis AG
16.16. Pfizer Inc.
16.17. Sanofi S.A.
16.18. Takeda Pharmaceutical Company Limited
16.19. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL TAXANES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL TAXANES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL TAXANES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HORMONE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL HORMONE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIANDROGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIANDROGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIANDROGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CYP17 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CYP17 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CYP17 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GNRH AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GNRH AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GNRH AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BETA EMITTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BETA EMITTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PARP INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PARP INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PARP INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOMECARE PROVIDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOMECARE PROVIDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HOMECARE PROVIDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 137. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 138. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 139. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 140. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 141. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 142. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 144. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 159. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 160. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 161. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 162. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 163. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 164. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 165. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 166. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 171. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 172. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 173. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 174. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 175. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 176. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 177. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 178. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 182. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 183. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 184. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 185. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 186. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 187. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 188. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 189. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 204. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 205. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 206. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 207. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 208. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 209. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 210. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 211. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 215. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 216. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 217. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 218. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 219. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 220. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 221. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 222. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 226. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 227. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 228. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 229. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 230. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 231. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 232. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 233. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 249. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 250. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 251. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 252. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 253. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 254. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 255. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 256. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 260. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 261. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 262. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 263. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 264. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 265. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 266. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 267. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 293. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 294. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 295. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 296. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 297. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 298. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 299. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 300. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 304. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 305. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 306. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 307. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 308. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 309. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 310. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 311. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 326. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 327. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2017-2032 (USD MILLION)
TABLE 328. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 329. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 330. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 331. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2017-2032 (USD MILLION)
TABLE 332. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 333. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2017-2032 (USD MILLION)
TABLE 33

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Ipsen S.A.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.84 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.59 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Prostate Cancer Therapeutics - Global Strategic Business Report - Product Image

Prostate Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
Prostate Health Market - Global Forecast 2026-2032 - Product Image

Prostate Health Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2026-2032 - Product Image

Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Castrate-Resistant Prostate Cancer - Global Strategic Business Report - Product Image

Castrate-Resistant Prostate Cancer - Global Strategic Business Report

  • Report
  • 178 Pages
  • Global
From
Prostate Cancer Therapeutics Market - Product Image

Prostate Cancer Therapeutics Market

  • Report
  • 150 Pages
  • Global
From

About the Prostate Cancer Drugs Market

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy. The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.